Related Experiment Video

Updated: Aug 15, 2026

Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation
10:24

Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation

Published on: September 19, 2019

Stochastic modeling of drug resistance in cancer

Natalia Komarova1

  • 1Department of Mathematics and Ecology and Evolution, University of California, Irvine, CA 92697, USA. komarova@math.uci.edu

Journal of Theoretical Biology
|October 1, 2005
PubMed

Insights

Developing drug resistance is a key challenge in cancer treatment. Mathematical modeling reveals that for non-mutagenic drugs, pre-existing resistance is more significant than treatment-induced resistance, especially in simultaneous multi-drug therapies.

Area of Science:

  • Mathematical Biology
  • Cancer Research
  • Pharmacology

Background:

  • Cancer treatment failure is often due to drug resistance.
  • Multi-drug therapies are a promising strategy to overcome resistance.
  • Understanding the dynamics of resistance is crucial for effective treatment.

Purpose of the Study:

  • To formulate and analyze a stochastic model for multi-drug resistance.
  • To investigate the impact of initial tumor load, mutation rates, and cell turnover on treatment outcomes.
  • To elucidate the principles of resistant cell evolution before and after treatment initiation.

Main Methods:

  • Stochastic mathematical modeling.
  • Analysis of cancer cell dynamics under drug pressure.
  • Investigation of treatment outcome dependencies.

Main Results:

  • For non-mutagenic drugs, pre-existing resistance is a greater driver than treatment-induced resistance, particularly with simultaneous drug application.
  • Treatment success is independent of cell turnover rate for single-drug therapy but strongly dependent for multi-drug therapies.
  • Increasing drug numbers improves success probability at low turnover rates; benefits diminish at very high turnover rates.

Conclusions:

  • The timing and combination of drugs are critical in managing cancer drug resistance.
  • Tumor cell turnover rate significantly influences the efficacy of multi-drug cancer therapies.
  • Mathematical modeling provides insights into optimizing therapeutic strategies against resistant cancers.

More Related Videos

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...